Medigen applies for phase 2 COVID-19 vaccine trial
Staff writer, with CNA
Medigen Vaccine Biologics Corp (高端疫苗) has applied to begin phase 2 testing of its COVID-19 vaccine, becoming the third local developer to seek permission to test the efficacy of its product on a larger scale, following Adimmune Corp (國光生技) and United Biomedical Inc (聯亞生技).
All participants in its phase 1 trial had completed the two-dose regimen of the vaccine, allowing researchers to obtain data on its safety and ability to elicit an immune response, Medigen said in a statement on Tuesday.
The company said that it had applied to the Food and Drug Administration for permission to begin phase 2 clinical trials to test the vaccine’s efficacy on 3,700 volunteers.